RPE65 and Bardet-Biedl syndrome: Indeed, gene therapy in RPE65 congenital BBS is not effective because patients carrying this mutation do not have sufficient target cells available to ensure therapeutic benefit with the restoration of a healthy RPE65 gene [126].